Globus Medical (NYSE:GMED) Updates FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.950-5.050 for the period, compared to the consensus earnings per share estimate of 4.740. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. UBS Group assumed coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price for the company. Royal Bank Of Canada lowered their price objective on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Globus Medical Stock Performance

Shares of Globus Medical stock traded up $0.72 on Thursday, hitting $81.26. The stock had a trading volume of 2,195,988 shares, compared to its average volume of 1,487,304. The stock has a 50 day moving average of $79.35 and a 200 day moving average of $85.34. Globus Medical has a twelve month low of $52.69 and a twelve month high of $101.40. The firm has a market capitalization of $11.03 billion, a P/E ratio of 18.90, a PEG ratio of 1.68 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts expect that Globus Medical will post 4.74 earnings per share for the current year.

Insider Activity

In other news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC acquired a new position in Globus Medical during the 3rd quarter worth about $26,000. EverSource Wealth Advisors LLC increased its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Parallel Advisors LLC raised its position in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of Globus Medical during the fourth quarter worth about $51,000. Finally, Headlands Technologies LLC lifted its stake in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.